CAMBRIDGE, UK – 3 December 2018 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect. Dr Edmunds has over 15 years’ pharmaceutical industry experience and a […]
Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities CAMBRIDGE, UK and NORTH CHICAGO, ILL, USA – 15th November 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global […]
CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect. Judit has over ten […]
CAMBRIDGE, UK – 8 March 2018 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group […]
CAMBRIDGE, UK – 1 March 2018 – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect. Dr Thompson has over 15 years’ experience in translational research […]
CAMBRIDGE, UK –15 November 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, fibrosis, and other diseases with high unmet medical need, is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience […]
CAMBRIDGE, UK – November 1 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, is presenting research and preclinical data on its USP30 inhibitor Parkinson’s disease programmes as two posters at Neuroscience 2017, the 47th Annual Meeting of the Society for […]
Preclinical data will be presented on novel USP30 inhibitors being developed as potential therapies for Parkinson’s disease Program of research supported by grant from The Michael J. Fox Foundation for Parkinson’s Research CAMBRIDGE, UK – 30 October 2017 – Mission Therapeutics announced that its Medical Director, CNS Translational Medicine, Dr Paul Thompson will be delivering […]
Keynote Nature article reviews drug discovery opportunities in multiple disease areas of unmet need CAMBRIDGE, UK – 29 September 2017 – An article entitled “Deubiquitylating enzymes (DUBs) and drug discovery: emerging opportunities,” written by the drug discovery team at Mission Therapeutics was published online today in the scientific journal Nature Reviews Drug Discovery. The peer-reviewed […]
Corporate & Development
McClintock Building
Granta Park
Great Abington
Cambridge
CB21 6GP
United Kingdom
T: +44 (0)1223 607 340
Research Facilty
Moneta (Building 280)
Babraham Research Campus
Cambridge
CB22 3AT
United Kingdom
T: +44 (0)1223 607 340
